Sara M. Tolaney

35.7k total citations · 18 hit papers
502 papers, 14.8k citations indexed

About

Sara M. Tolaney is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sara M. Tolaney has authored 502 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 414 papers in Oncology, 295 papers in Pulmonary and Respiratory Medicine and 173 papers in Cancer Research. Recurrent topics in Sara M. Tolaney's work include Advanced Breast Cancer Therapies (237 papers), HER2/EGFR in Cancer Research (217 papers) and Cancer Treatment and Pharmacology (149 papers). Sara M. Tolaney is often cited by papers focused on Advanced Breast Cancer Therapies (237 papers), HER2/EGFR in Cancer Research (217 papers) and Cancer Treatment and Pharmacology (149 papers). Sara M. Tolaney collaborates with scholars based in United States, Spain and Germany. Sara M. Tolaney's co-authors include Romualdo Barroso‐Sousa, Eric P. Winer, Sònia Pernas, Tanya E. Keenan, Paolo Tarantino, Ian E. Krop, Hope S. Rugo, Le Min, F. Stephen Hodi and William T. Barry and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Sara M. Tolaney

470 papers receiving 14.6k citations

Hit Papers

Incidence of Endocrine Dysfunction Following the Use of D... 2014 2026 2018 2022 2017 2014 2019 2018 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
    2017 768 citations Romualdo Barroso‐Sousa, F. Stephen Hodi et al. profile →
  2. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →
  3. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    2019 599 citations Sara M. Tolaney, Joyce O’Shaughnessy et al. profile →
  4. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
    2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
  5. HER2-Low Breast Cancer: Pathological and Clinical Landscape
    2020 490 citations Paolo Tarantino, Sara M. Tolaney et al. Journal of Clinical Oncology profile →
  6. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
    2017 490 citations Sara M. Tolaney, Hope S. Rugo et al. Clinical Cancer Research profile →
  7. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations Sara M. Tolaney, Denise A. Yardley et al. profile →
  8. Role of Immunotherapy in Triple-Negative Breast Cancer
    2020 400 citations Sara M. Tolaney et al. profile →
  9. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
    2018 357 citations Romualdo Barroso‐Sousa, Sara M. Tolaney et al. profile →
  10. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
    2019 314 citations Sara M. Tolaney, Antoinette R. Tan et al. profile →
  11. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
    2021 275 citations Paolo Tarantino, Chiara Corti et al. profile →
  12. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
    2019 256 citations Sara M. Tolaney et al. profile →
  13. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
    2023 210 citations Hope S. Rugo, Javier Cortés et al. profile →
  14. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2022 176 citations Hope S. Rugo, Javier Cortés et al. Journal of Clinical Oncology profile →
  15. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
    2022 147 citations Paolo Tarantino, Nabihah Tayob et al. profile →
  16. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
    2022 147 citations Paolo Tarantino, Chiara Corti et al. profile →
  17. Optimizing the safety of antibody–drug conjugates for patients with solid tumours
    2023 139 citations Paolo Tarantino, Sara M. Tolaney et al. profile →
  18. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
    2024 71 citations Hope S. Rugo, Sara M. Tolaney et al. Journal of Clinical Oncology profile →

Peers

Sara M. Tolaney
Comparison fields: 5 of 141
  • Oncology 11.6k
  • Pulmonary and Respiratory Medicine 5.3k
  • Cancer Research 3.7k
  • Molecular Biology 2.8k
  • Radiology, Nuclear Medicine and Imaging 2.0k
Replace Nancy U. Lin with:
Nancy U. Lin United States
Carlos H. Barrios Brazil
Angelo Di Leo Italy
Luc Dirix Belgium
Christophe Massard France
Igor Bondarenko United States
Ian E. Krop United States
Young‐Hyuck Im South Korea
Shahneen Sandhu Australia
Sara A. Hurvitz United States
Nancy U. Lin United States View profile →
Citations per field, relative to Sara M. Tolaney
Sara M. Tolaney · 1×
Citations per year, relative to Sara M. Tolaney
Sara M. Tolaney · 1×

Countries citing papers authored by Sara M. Tolaney

Since Specialization
Citations

This map shows the geographic impact of Sara M. Tolaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara M. Tolaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara M. Tolaney more than expected).

Fields of papers citing papers by Sara M. Tolaney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara M. Tolaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara M. Tolaney. The network helps show where Sara M. Tolaney may publish in the future.

Co-authorship network of co-authors of Sara M. Tolaney

This figure shows the co-authorship network connecting the top 25 collaborators of Sara M. Tolaney. A scholar is included among the top collaborators of Sara M. Tolaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara M. Tolaney. Sara M. Tolaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
2025 ·Clinical Cancer Research ·Sara M. Tolaney, Thomas M. Cardillo, Chih-Chien Chou, (unknown), Mary Faris
5
2
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
2025 ·Clinical Cancer Research ·Shom Goel, Bojana Jovanović, (unknown), Melissa E. Hughes, (unknown), (unknown), (unknown), Eileen Wrabel, Rinath Jeselsohn, Nancy U. Lin, Nabihah Tayob, Elizabeth A. Mittendorf, Stuart J. Schnitt, Sara M. Tolaney
3
3
Globalization of clinical research in oncology: Status, challenges, and future directions
2024 ·Journal of Cancer Policy ·(unknown), Robert Šeparović, Sara M. Tolaney, Dario Trapani
3
4
433TiP Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
2024 ·Annals of Oncology ·Sara M. Tolaney, Paolo D’Amico, (unknown), Kim M. Hirshfield, (unknown)
2
5
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
2023 ·Cancers ·Romualdo Barroso‐Sousa, (unknown), Sarah Sammons, Sara M. Tolaney
24
6
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 ·ESMO Open ·Gabriele Antonarelli, Chiara Corti, Paolo Tarantino, Beatrice Taurelli Salimbeni, Paola Zagami, Antonio Marra, Dario Trapani, Sara M. Tolaney, Javier Cortés, Giuseppe Curigliano
21
7
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
2023 ·Cancers ·Abhenil Mittal, (unknown), (unknown), Ilana Schlam, Sarah Sammons, Sara M. Tolaney, Paolo Tarantino
21
8
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2
2023 ·Critical Reviews in Oncology/Hematology ·Ilana Schlam, (unknown), Stefania Morganti, Sara M. Tolaney, Paolo Tarantino
16
9
274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
2023 ·Annals of Oncology ·Joyce O’Shaughnessy, (unknown), Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen Johnston, M. Martín Jiménez, Priya Rastogi, Nadia Harbeck, Hope S. Rugo, Ran Wei, Valérie André, Ashwin Shahir, Matthew P. Goetz
1
10
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
2023 ·Frontiers in Oncology ·Sarah Sammons, Andrew Elliott, Romualdo Barroso‐Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Evanthia T. Roussos Torres
4
11
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
2021 ·Clinical Cancer Research ·Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O’Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou, Debra A. Patt, Yuan Yuan, Grace Wang, (unknown), Dongyuan Xing, (unknown), Vassiliki Karantza, Sami Diab
90
12
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
2021 ·Breast Cancer Research and Treatment ·José Pablo Leone, Bernardo Amadeo Leone, Nabihah Tayob, Michael J. Hassett, Julieta Leone, Rachel A. Freedman, Sara M. Tolaney, Eric P. Winer, Carlos Vallejo, Nancy U. Lin
9
13
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial
2020 ·Cancer Prevention Research ·Justin C. Brown, Sui Zhang, Jennifer A. Ligibel, Melinda L. Irwin, Lee W. Jones, Nancy Campbell, Michaël Pollak, (unknown), Brenda Cartmel, Maura Harrigan, Sara M. Tolaney, Eric P. Winer, Kimmie Ng, Thomas A. Abrams, Tara Sanft, Pamela S. Douglas, Frank B. Hu, Charles S. Fuchs, Jeffrey A. Meyerhardt
31
14
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
2020 ·Clinical Cancer Research ·Sara M. Tolaney, T. Khanh, Joseph P. Eder, Patricia LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Ching‐Wei Chang, (unknown), (unknown), (unknown), Flávia Brunstein, Montserrat Carrasco‐Triguero, Walter C. Darbonne, Jennifer M. Giltnane, W. Michael Flanagan, S. Renee Commerford, Alexander Ungewickell, Geoffrey I. Shapiro, Shanu Modi
15
15
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
2020 ·Clinical Cancer Research ·Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, Pierfranco Conté, Véronique Dièras, Nancy U. Lin, (unknown), Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
144
16
The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders
2019 ·Cancer Immunology Research ·(unknown), F. Stephen Hodi, Anita Giobbie‐Hurder, Xiaocheng Wang, Jing Zhou, Amy Zhang, Ying Zhou, Fei Mao, Trevor E. Angell, Chelsea Andrews, Jiani Hu, Romualdo Barroso‐Sousa, Ursula B. Kaiser, Sara M. Tolaney, Le Min
49
17
Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses
2017 ·Cancer Research ·Peter Schmid, Cristina Cruz, Fadi S. Braiteh, Joseph P. Eder, Sara M. Tolaney, Irene Kuter, Rita Nanda, Cathie T. Chung, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Yijin Li, Bo Liu, Carol O’Hear, Marcella Fassò, Luciana Molinero, Leisha A. Emens
92
18
Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.
2017 ·Journal of Clinical Oncology ·Sara M. Tolaney, Nancy U. Lin, Donald Thornton, Suzanne Klise, Timothy M. Costigan, P. Kellie Turner, Carey K. Anders
41
19
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) breakdown →
2014 ·Journal of Clinical Oncology ·William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance Cirrincione, Sara M. Tolaney, Charles Kuzma, Timothy Pluard, George Somlo, Elisa Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer
650
20
Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
2013 ·Clinical Cancer Research ·David A. Proia, Chaohua Zhang, Manuel Sequeira, John-Paul Jimenez, Suqin He, Neil L. Spector, Geoffrey I. Shapiro, Sara M. Tolaney, Masazumi Nagai, Jaime Acquaviva, Donald L. Smith, Jim Sang, Richard C. Bates, Iman El‐Hariry
53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy U. Lin Breakdown of academic impact, for papers by Carlos H. Barrios Breakdown of academic impact, for papers by Angelo Di Leo Breakdown of academic impact, for papers by Luc Dirix Breakdown of academic impact, for papers by Christophe Massard Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Ian E. Krop Breakdown of academic impact, for papers by Young‐Hyuck Im Breakdown of academic impact, for papers by Shahneen Sandhu Breakdown of academic impact, for papers by Sara A. Hurvitz
Rankless by CCL
2026